Abstract The major psychoactive component of marijuana, Δ 9
Introduction
Self-administered marijuana use is common and can exceed 50 % among human immunodeficiency virus-1 (HIV-1) positive adolescents (National Institute on Drug Abuse 2012; Nichols et al. 2014; Rotheram-Borus et al. 1997 ). In addition, Dronabinol, a synthetic form of delta-9-tetrahydrocannabinol (THC), the major psychoactive constituent of marijuana, is an FDA approved drug prescribed to diminish AIDS-associated weight loss (Ben Amar 2006) .
THC interacts with cells primarily via cannabinoid receptors 1 and 2 (CB 1 and CB 2 , respectively). CB 1 and CB 2 are Gprotein coupled seven-transmembrane molecules that normally function as receptors for endocannabinoids (Devane et al. 1992 ). More recently a third G-protein coupled receptor, GPR55, which binds THC and the endogenous ligand lysophosphatidylinositol, was identified (Henstridge et al. 2011 ). Receptor expression is complex and can be modulated by anatomical location, cell lineage, and stage of differentiation. For example, CB 1 is distributed throughout the brain (Matsuda et al. 1990 ), but is also detected on peripheral immune cells (Galiègue et al. 1995; Han et al. 2009 ). CB 2 is predominantly expressed on immune cells (Castaneda et al. 2013; Galiègue et al. 1995; Han et al. 2009 ), but appears on microglia cells during inflammation and HIV-1 infection (Cabral and Marciano-Cabral 2005; Ramirez et al. 2013) . GPR55 is expressed most abundantly in brain, intestine, and spleen but is also found on macrophages (Henstridge et al. 2011) . Monocytes express CB 2 and GPR55, but little if any CB 1 , although differentiation into macrophages increases levels of CB 1 and reduces levels of CB 2 compared with monocytes (Galiègue et al. 1995; Han et al. 2009; Whyte et al. 2009 ).
THC exhibits immune suppressive and anti-inflammatory effects on murine and human cells of monocyte/macrophage lineage (Chang et al. 2001; Coffey et al. 1996; Shivers et al. 1994) . Macrophages provide long-lived environments for HIV-1 infection, which can prime infected cells leading to hyper-responsiveness to activation. As regulators of cellular immune responses, macrophages contribute to generalized immune dysfunction associated with HIV-1 infection. Macrophage activation resulting from HIV-1 infection persists for years even after initiation of antiretroviral therapy (ART) (Wallet et al. 2010 ) and is likely a significant contributor to chronic inflammation and inflammation-related pathogenesis (Hunt 2012) .
Cannabinoids modulate a number of virus infections, in some cases enhancing pathogenesis, but in other cases inhibiting reactivation from latency. For example, THC administration in murine models enhances disease severity and duration by vaccinia virus infection (Huemer et al. 2011) , while attenuating cellular infiltration and increasing influenza viral load (Buchweitz et al. 2007 ). Kaposi's sarcoma virus (KSV) infection of human microvascular endothelial cells is enhanced by THC treatment (Zhang et al. 2007 ), but THC inhibits KSV or Epstein Barr virus reactivation in immortalized B cells (Medveczky et al. 2004) . In vitro, HIV-1 infection of human CD4 + T cells or macrophages is attenuated by CB 2 specific agonists (Costantino et al. 2012; Ramirez et al. 2013) , while chronic THC administration to rhesus macaques prior to simian immune deficiency virus (SIV) infection suppresses IFN-γ levels in lymph nodes, attenuates SIV levels in plasma and cerebral spinal fluid, and prolongs the life of the animals (Molina et al. 2011a, b) . Although THC appears to have a suppressive effect on virus infection in a number of studies, data can be conflicting and mechanisms of THC effect, particularly on HIV-1 infection of macrophages, are unclear.
Since, HIV-1 infected individuals use marijuana, and are thus exposed to THC, and macrophages are targets for HIV-1 infection and express cannabinoid receptors, THC may impact HIV-1 infection of macrophages, although whether the outcome is harmful or beneficial, remains unclear. Therefore, we designed a study to investigate the effects of THC ex vivo on macrophage susceptibility to HIV-1 infection.
Materials and Methods

Cell Culture
Monocyte derived macrophages (MDM) were generated from elutriated human monocytes provided by Dr. Howard Gendelman at the University of Nebraska (Gendelman et al. 1988) or Dr. Mark Wallet at the University of Florida. Use of human cells was approved by the institutional review boards of the University of Nebraska and University of Florida. MDM were cultured as previously described (Wallet et al. 2012 (Fig. 1) . In treatment 1, monocytes received THC or vehicle control on days -7 and -5 concurrent with MCSF treatment during differentiation into MDM. In treatment 2, MDM were differentiated and treated with THC or vehicle control 30 min prior to infection. Finally, in treatment 3, MDM were treated with THC or vehicle control on post infection days 1, 4, and 7. Toxicity of THC or cannabinoid receptor agonists was evaluated by MTS viability assays; briefly, MDM were incubated with CellTiter 96 Aqueous One Solution (Promega, Madison, WI) for 3 h and absorbance measured at a wavelength of 490 nm using a universal microplate reader (BioTek Instrument Inc, Winooski, VT). Cell viability after THC treatments was 92-105 % compared to untreated or vehicle treated cells.
HIV-1 Infection of Macrophages
Virus stocks of the CCR5 using, macrophage tropic, replication competent HIV-1 AD were prepared by transfecting plasmid DNA from a molecular clone into 293T cells and titered as described previously (Theodore et al. 1996) . MDMs were infected for 24 h with HIV-1 AD (MOI=0.005). On postinfection day (PID) 1 media was removed, cells washed with PBS, and fresh media added. Supernatants were collected on PID 4, 7, and 10 and levels of p24 antigen were assessed using p24 ELISA kits (Sino Biological Inc., Beijing, China). Single cycle, luciferase-tagged HIV-1 JRFL envelope pseudotyped virus particles were produced as previously described, titered on TZM-bl cells (Tuttle et al. 2002) , and used to infect MDM for 24 h (MOI=0.0005). On PID 1, media was removed, cells washed with PBS, and fresh media added. On PID 4, media was removed, cells lysed, and luciferase activity was determined as relative light units (RLU) using the luciferase assay system (Promega, Madison, WI) and the microplate luminometer Monolight 3096 (BD Biosciences, San Jose, CA).
Flow Cytometry
Macrophages were differentiated in UpCell tissue culture plates (Thermo Scientific Nunc, Rochester, NY). After indicated times, cells were released from plates according to manufacturer's protocol and stained in 0.5 % BSA and 1 mM EDTA in PBS using the following antibodies, anti-CCR5 APC, anti-CXCR4 PE, anti-CD14 Pacific Blue, anti-CD16 PE-Cy7, anti-ICAM-1 PE, anti-CD11b FITC (BD Biosciences, San Jose, CA), anti-CD4 FITC, anti-CD163 APC (ebioscience, San Diego CA), anti-MAC387-FITC (Abcam, Cambridge, MA) or anti-p24 PE antibody (KC57-RD1) (Beckman Coulter Indianapolis, IN). For intracellular p24 staining, cells were permeabilized and stained using the BD Cytofix/Cytoperm kit according to manufacturer's instructions (BD Biosciences, San Jose, CA). Flow cytometry was performed using a LSRII flow cytometer (BD Biosciences, San Jose, CA). Data were analyzed using Flow Jo software (Treestar, Ashland, OR).
Quantification of Supernatant p24 per Infected Cell
Flow cytometry was used to quantitate infected cells based on the presence of intracellular p24, while picogram (pg) of p24 released into the supernatant was quantified by ELISA (Biological Inc., Beijing, China). Amount of supernatant p24 was divided by total number of infected cells in the well, and this ratio was converted to pg of p24 released per 1,000 infected cells.
Quantitative Real Time PCR Total RNA from MDM was extracted using the Ambion RNAqueous-4PCR Kit (Invitrogen, Life Technologies, Grand Island, NY) according to the manufacturer's instructions. Samples were treated with DNAse 1 and RNA concentrations were quantified. cDNA was synthesized using equal concentrations of RNA and SuperScript III First-Strand Synthesis SuperMix for qRT-PCR (Invitrogen, Grand Island, NY) per manufacturer's instructions. The qRT-PCR was performed using SYBER Select Master Mix (Applied Biosystems, Life Technologies, Grand Island, NY) and primers specific for APOBEC3G, SAMHD1, Cyclophilin A , actin (Qiagen, Germantown, MD) TRIM5α or Tetherin (IDT, Coralville, Iowa). Data was first normalized to the endogenous control, actin, and then expressed as a relative fold change compared to results from vehicle treated cells.
For HIV-1 gag and ApoB copies, DNA was extracted from cells 24 h post infection by HIV-1 AD using the DNeasy blood and tissue kit from Qiagen (Germantown, MD) and quantified by qRT-PCR using a TaqMan assay as previously described (Coberley et al. 2004 ). All qRT-PCR was performed using the ABI 7500 FAST instrument (Applied Biosystems, Life Technologies, Grand Island, NY).
Hypermutation Analysis
Genomic DNA was isolated from MDM infected with HIV-1 AD using DNeasy Blood and Tissue DNA isolation kit (Qiagen, Germantown, MD). A 460 base pair portion of viral DNA, corresponding to HXB2 coordinates 2147-2610, was amplified with the following program 95°C for 2 min, 30 cycles of 95°C for 15 s, 55°C fpr 15 s, 45°C for 45 s, followed by 1 cycle of 68°C for 5 min using Platinum Taq (Invitrogen, Life Technologies, Grand Island, NY) and the following forward and reverse primers, CAGAGCCAACAG CCCCACCAG and CTTTTGGGCCATCCATTCCTGGC, respectively. PCR products were ligated in TOPO-TA pCR 2.1 vector (Invitrogen, Life Technologies, Grand Island, NY). Samples were transformed and colonies were grown overnight. Sanger sequencing was performed by the UF ICBR Sequencing core facility. Quality sequences [at least 50 per treatment] were aligned and hypermutation was assessed using the Hypermut tool (Los Alamos National laboratory).
Statistical Analysis
Statistical analyses were performed using Graph Pad Prism software (La Jolla, CA). One or two way ANOVA and Bonferroni's post-test or t-tests were used where appropriate as indicated in figure legends. p-values less than 0.05 were considered statistically significant. Three to six replicate wells were examined in each experiment. Each experiment was performed in cells from multiple independent donors as indicated in figure legends (Bol et al. 2009 ).
Results
THC Treatment During Differentiation Reduces HIV-1 Replication in MDM
To determine if THC modulates HIV-1 replication, monocytes or MDM were treated with THC using three different treatment schemes (described in Materials and Methods, Fig. 1 ) and infected by macrophage tropic, CCR5 using, replication competent, HIV-1 AD . Monocytes treated during differentiation with THC at 1, 10 or 30 μM concentrations (Treatment 1) showed a concentration dependent decrease in supernatant p24 levels relative to vehicle controls (Fig. 2a) . THC at 30 μM significantly reduced, but failed to completely suppress, p24 production on days 7 or 10 of infection. Although p24 production varied amongst donors, 30 μM THC mediated suppression ranged from 2 to 25 fold, (mean of 6 fold) on PID 7 and 10. In contrast to THC treatment during differentiation, no differences in supernatant p24 levels were detected when MDM were exposed to a single THC treatment 30 min prior to infection (Treatment 2) (Fig. 2b) or a series of THC treatments following HIV-1 infection (Treatment 3) (Fig. 2c) . Results indicate that THC treatment of monocytes during differentiation subsequently altered HIV-1 infection in resultant MDM. To determine if THC reduces initial infection or diminishes virus production per cell, the percent of infected MDM was evaluated by intracellular p24 staining using flow cytometry. Significantly fewer p24 positive macrophages were observed on PID 7 and 10 in the cells treated with THC during differentiation (Treatment 1) compared to untreated or vehicle treated cells (Fig. 2g) . Average percent p24 + reduction across experiments from three donors was 3.5 fold for PID 7 and 5.5 fold on PID 10. While the percent of p24 + cells in untreated or vehicle treated cells increased over 15-fold from PID 4 to 10, the percent p24 + macrophages treated with THC during differentiation increased about 3-fold (Fig. 2g) . However, when infection was examined as release of p24 into the supernatant per 1,000 infected cells, similar values were observed across treatments (Fig. 2h) . Results suggest that THC reduces the potential of cells to be infected with little to no effect on virus replication or production within an infected cell.
THC Inhibits Early Events of HIV-1 Infection in MDM
To examine first round replication, monocytes were differentiated in the presence of THC (Treatment 1) and infected by single-cycle CCR5-envelope pseudotyped viruses (HIV-1 JRFL ). A dose dependent reduction, to a maximum of 70 %, in luciferase activity was observed (Fig. 2d) . Across five donors, the average RLU reduction induced by 10 μM THC was 2.1 fold while 30 μM was 16 fold; in contrast, no differences were found when MDM were treated with any concentration of THC either immediately prior to (Treatment 2) or following infection (Treatment 3) ( Fig. 2e and f respectively). To examine initial infection, viral gag copies were quantified after 24 h of HIV-1 AD infection. MDM cultures treated with 30 μM THC during differentiation had significantly reduced gag copies (4 to 5 fold fewer) compared to vehicle treated cells (Fig. 2i) . Taken together, these data support a model of reduced cell infection that could reflect modulation of entry and/or first round replication by THC treatment during differentiation. CB 2 , but Not CB 1 or GPR55, Specific Agonist Suppresses HIV-1 Replication in MDM To determine if the THC effect on viral infection was mediated through cannabinoid receptors CB 1 , CB 2 , or GPR55, monocytes were differentiated into MDM in the presence of cannabinoid receptor agonists, vehicle alone, or left untreated prior to infection (Treatment 1). MDM differentiated in the presence of 10 μM CP55,940 (pan cannabinoid receptor agonist) showed significantly lower supernatant p24 levels compared to vehicle control by days 7 and 10 post-infection (Fig. 3a) . MDM treated during differentiation with the CB 2 specific agonist, JWH-133, also showed a decrease in viral production, with an average reduction on day 10 post infection of 7.1 fold at the 10 μM dose across experiments from three donors (Fig. 3b) . In contrast, MDM treated during differentiation with ACEA, a CB 1 specific agonist, or O-1602, a GPR55 specific agonist, showed no decrease in p24 levels ( Fig. 3c and d) . Overall, results indicate that activation of the CB 2 receptor plays a significant role in suppression of HIV-1 replication in MDM treated with THC during differentiation.
Differentiation of MDMs in the Presence of THC Inhibits HIV-1 Receptor Expression
Since the inhibitory mechanism of THC treatment appears to diminish entry and/or first round replication, cell surface levels of CD4, CCR5, and CXCR4, receptors used by HIV-1 for entry, were evaluated. Compared to treatment by vehicle control or untreated cells, monocytes treated with 30 μM THC during differentiation into MDM (Treatment 1) displayed reduced cell surface expression of each HIV-1 receptor after 7 days of differentiation (Fig. 4a-c) . To determine the kinetics of the THC effect on HIV-1 receptors during differentiation, cell surface expression of CD4, CCR5 and CXCR4 was evaluated over the course of differentiation. Surface expression of CD4 and CCR5 was significantly reduced after only 1 day of exposure to THC (Fig. 4d and e) . CD4 levels continued to decline to a maximum of approximately 50 % of untreated on days 5 and 7 (Fig. 4d) , while maximal reduction in CCR5 expression to approximately 50 % of untreated persisted over time (Fig. 4e) . CXCR4 surface expression was significantly reduced on days 3 and 5 of differentiation with maximal reduction at approximately 65 % of untreated (Fig. 4f) . Overall, monocyte exposure to THC during differentiation reduced HIV-1 receptor CD4 and CCR5 cell surface protein levels, which would limit viral entry and diminish infection of macrophages.
Differentiation of MDM in the Presence of THC Alters Cell Surface Marker Phenotype
Since HIV receptors are modulated during monocyte to macrophage differentiation, we next examined the phenotype of (Fischer-Smith et al. 2008) . Therefore, CD14, CD16 and CD163 surface expression levels were assessed and all were reduced by differentiation in the presence of THC (Treatment 1) (Fig. 5a-c) . To investigate the kinetics of the THC effect, cell surface expression of CD14, CD16 and CD163 was evaluated after 1, 3, 5 and 7 days of differentiation. Expression of CD14 declined over time and was significantly reduced on days 3, 5 and 7 of differentiation with a maximal reduction to approximately 45 % of untreated cells (Fig. 5d) . Expression of CD16 and CD163 rapidly declined to approximately 30 % of untreated cells, and remained suppressed over time ( Fig. 5e and f) . The THC effect on phenotype was selective, in that cell surface receptors CD11b, ICAM-1 and intracellular marker Mac 387 were not altered by THC treatment (Fig. 5g, h and i) . Results indicate that THC treatment during monocyte differentiation selectively modifies MDM phenotype.
THC Treatment During Differentiation Results in Elevated Levels of Viral Restriction Factors
Host viral restriction factors are expressed at higher levels in monocytes and downregulated during differentiation (Bergamaschi and Pancino 2010) , therefore we examined the effect of THC on mRNA levels of host cell viral restriction factors, including cyclophilin A, tetherin, TRIM5α, SAMHD1, and APOBEC3G (Fig. 6) . THC treatment of differentiating macrophages (Treatment 1) produced no differences in steady state mRNA levels for cyclophilin A or tetherin. In contrast, steady state levels of APOBEC3G, SAMHD1, and TRIM5α were increased by about 1.5 to 2.5-fold over vehicle with evident donor variability (p<0.05, p<0.01, p=0.18 respectively). Results support alteration of MDM phenotype by THC that might restrict virus replication.
To determine if elevated APOBEC3G mRNA corresponded with increased hypermutation of HIV-1 genomes, frequency of G to A substitutions in sequences of a 400 bp region of HIV-1 that includes protease were evaluated in infected THC treated, vehicle treated or untreated macrophages. Fewer than 5 % of sequences showed one or more G to A transitions, with no differences in frequency of G to A substitutions between THC or control treated cells. In addition, less than 3 % of sequences displayed an APOBEC3G hypermutation signature independent of THC treatment.
Discussion
Our study uncovered a novel inhibitory function of THC in HIV-1 infection of macrophages. Administration of THC during macrophage differentiation rendered the cells less susceptible to HIV-1 infection concomitant with a dramatic reduction in surface expression of HIV receptors CD4 and CCR5. THC treatment of monocytes primarily modifies entry steps of HIV infection, with little to no effect post entry, and modulates macrophage phenotype.
Monocyte/macrophage differentiation state alters HIV receptor expression and infection (Bergamaschi and Pancino 2010; Tuttle et al. 1998) . Functional receptors are required for HIV infection of MDM as anti-receptor antibodies, pharmacologic inhibitors, such as Maraviroc, and soluble CD4 severely diminish infection (O'Connell et al. 2013; Surdo et al. 2013; Tuttle et al. 1998) . Similarly, a number of studies have demonstrated that HIV-1 receptor expression levels modulate entry kinetics on a variety of target cells, including lymphocytes and macrophages (Anderson and Akkina 2005;  Anderson et al. 2003; Chikere et al. 2013; Johnston et al. 2009; Keele et al. 2008) . Despite an increase in host restriction factor mRNA, a role for THC in the control of viral infection post entry was not apparent in our study. Moreover, infected cells released similar levels of p24 into the supernatant independent of THC treatment. Results taken together led us to conclude that THC mediated reduction in HIV-infected cells is due to a reduction in HIV receptor cell surface expression. Our study focused on CCR5-using viruses, including replication competent HIV-1 AD and single cycle HIV-1 JRFL enveloped virions, because of the persistence of macrophage tropic CCR5-using viruses throughout the course of infection. Given the importance of CD4 expression for infection and dramatic reduction in CD4 surface expression by THC, we expect that infection of macrophages differentiated in the presence of THC by a CXCR4 using virus would be similarly reduced.
Doses of THC used in our study to achieve suppression of HIV-1 infection are consistent with other publications with human cells (Shivers et al. 1994; Watzl et al. 1991; Zheng et al. 1992 ), but are nonetheless greater than THC levels detected in the circulation following marijuana use (Grotenhermen 2003) . This disparity is partially explained by our use of 10 % human serum in the monocyte cultures and the findings of a number of investigators that increasing the serum concentration in the tissue culture medium shifts the THC dose response to the right (Klein et al. 1985; Tang et al. 1993) . Over the past 40 years concentrations of THC in marijuana have increased more than 10 fold (Sevigny 2013) , and levels in the blood of drivers suspected of DUI have also increased (Vindenes et al. 2013) , so previous estimates of the concentration of THC and its metabolites in the circulation may not be reflective of levels in current chronic users. Cannabinoids and their metabolites accumulate at higher concentrations in fat, spleen and lymph nodes, compared to the brain and blood after administration in animal models (Ho et al. 1970; Kreuz and Axelrod 1973; Lynn and Herkenham 1994; Ryrfeldt et al. 1973 ). Consequently, current marijuana users may well have greater accumulation of THC in immune tissues compared to cells in circulation, which has The suppressive effect of exposure to THC during differentiation of MDM on HIV-1 infection is primarily mediated through CB 2 , consistent with monocytes expressing CB 2, but little if any CB 1 (Galiègue et al. 1995; Han et al. 2009 ). In addition, CP55,940 (a full CB 1 /CB 2 agonist) and THC (a partial CB 1 /CB 2 agonist) appear to have the same potency in suppressing p24 (Figs. 2 and 3) suggesting that THC might have non-receptor effects on the MDM as has been suggested by a number of previous studies (Newton and Klein 2012; Springs et al. 2008) . Suppression of HIV-1 infection using the CB 2 agonist, JWH-133, has been observed in MDM (Ramirez et al. 2013) , although in contrast to our study with THC, expression of HIV-1 receptors was unaltered. Differences between THC and JWH-133 as CB 2 ligands, multiplicity of infection, as well as infection and treatment schemes may explain our divergent results and point to multiple mechanisms, substantiating that the differentiation state of the target cells can impact THC responses. Treatment with a CB 1 agonist during differentiation failed to reduce infection in MDMs reflecting a lack of CB 1 expression on monocytes (Han et al. 2009) . A role in our study for signaling via GPR55 can also be ruled out, as no decrease of infection in MDMs differentiated in the presence of a GPR55 specific agonist occurred even though cells express GPR55 (Henstridge et al. 2011; Whyte et al. 2009 ). Differences in downstream signaling between CB 2 and GPR55 receptors can be used to identify signaling pathways critical for THC mediated suppression of HIV infection. CB 2 receptor signaling is associated with a G i/o protein, while GPR55 receptor signaling is mediated through activation of a Gα 13 protein (Cabral and Griffin-Thomas 2009; Henstridge et al. 2011) . Previous studies show that THC signaling via CB 2 and the associated G i/o protein leads to activation of signaling pathways involving cAMP, release of intracellular calcium and activation of the MAPK pathway (Bouaboula et al. 1996; Cabral and GriffinThomas 2009) . CB 2 mediated MAPK activation induces EGR1, a transcriptional regulator critical for macrophage differentiation and functioning (Bouaboula et al. 1996; McMahon and Monroe 1996) . Although, intracellular signaling pathways facilitating suppression of HIV-1 receptors and subsequent infection remains unclear; THC treatment prevents chemotaxis of mouse peritoneal macrophages to the CCR5 ligand, CCL5, in a CB 2 dependent manner; suggesting that THC can modulate signaling or expression of CCR5 (Cabral and Griffin-Thomas 2009; Raborn et al. 2008) . Similar signaling interactions by THC may modulate surface expression levels of CD4 or other chemokine receptors.
Our study is especially novel in that we discovered a treatment scheme in which exposure of monocytes to a drug alters the phenotype of the resultant macrophages. Others have found phenotypic alterations of MDM derived from monocytes infected by Mycobacterium tuberculosis (Castaño et al. 2011) or treated with corticosteroids (Rinehart et al. 1982) or butyrate, which diminishes macrophage expression of CD14 and CD16 (Millard et al. 2002) . Ultimately, it is conceivable that exposure to THC during differentiation may elicit global or selective changes to the cell, resulting in phenotypic reprograming.
THC mediated reduction in CD14, CD16, and CD163 could affect HIV-1 associated neurocognitive disorders (HAND). Cells expressing high levels of these markers can be infected in vivo (Ellery et al. 2007) , are associated with alterations in brain metabolism (Lentz et al. 2011 ) and migrate through the blood brain barrier (Buckner et al. 2011; Williams et al. 2012) . Ex vivo, THC reduces migration of macrophages to HIV-1 proteins (Raborn and Cabral 2010) . Taken together with our results, THC exposure may reduce HIV-1 infection in the brain by modulating CD14, CD16 and CD163 expressing cells and limiting migration.
Results from our study raise the possibility that extended marijuana use might decrease macrophage susceptibility to HIV-1 infection. Chronic exposure to marijuana may also fundamentally alter macrophage differentiation, which could result in functional differences in macrophages as regulators of immune responses and contributors to immune dysfunction. Increasing approval of marijuana and its derivatives for medical indications and elevating levels of THC in recreational marijuana necessitates further studies investigating the immunological effects of marijuana use. by the Laura McClamma Fellowship at the University of Florida. SA is supported by the University of Florida Alumni graduate fellowship and the Linton E. Grinter fellowship. Additional support was provided by the Robert A. Good endowed Chair in Immunology (University of South Florida), Stephany W. Holloway University Chair for AIDS Research (University of Florida), Center for Research in Pediatric Immune Deficiency and Inflammation, and University of Florida Health Cancer Center.
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